9.2 Biotechnology and its Applications
What the tools of recombinant DNA technology are used for: human insulin and recombinant vaccines, gene therapy, stem cells and molecular diagnosis; Bt crops and RNA interference; transgenic animals; and the biosafety, patent and biopiracy questions they raise.
In 1990 a four-year-old girl in the United States was born without a working copy of one gene — the gene for the enzyme adenosine deaminase. Without that enzyme her immune system could not work, and every infection was dangerous. Doctors took some of her white blood cells, gave them a working copy of the gene, grew them in the laboratory and put them back into her blood. She became the first person to receive gene therapy. In the same decade, farmers in several countries began sowing cotton that poisons the caterpillars that bore into its bolls, and a cow in the United States gave milk enriched with a human protein.
All of these rest on the tools of Section 9.1 — restriction enzymes, vectors, competent hosts, PCR and bioreactors. This section is about what they are for: in medicine (human insulin, recombinant vaccines, gene therapy, stem cells and molecular diagnosis), in agriculture (genetically modified crops, Bt cotton and pest resistance by RNA interference), in animals (transgenic mice, cows and others), and finally the rules a society needs once it can change genes — biosafety, patents and biopiracy. NEET questions on this section are mostly about exact facts (which gene, which pest, which year, which enzyme), so the page marks each one clearly.
Biotechnology in Medicine I — Human Insulin and Recombinant Vaccines
Before recombinant DNA, a protein drug had to be extracted from wherever nature made it: insulin from the pancreas of slaughtered animals, growth hormone from human pituitary glands taken after death, a vaccine from the pathogen itself. Every source was limited, and some were risky. Recombinant DNA technology changed the question from "where can we find this protein?" to "which cell shall we ask to make it?".
Recombinant therapeutics are drugs (usually proteins) made by organisms that carry the human or pathogen gene for them — that is, made by recombinant DNA technology. Because the protein is the human one, or exactly the antigen needed, it does not set off the unwanted immunological responses seen with similar products isolated from non-human sources, and it can be produced safely, in bulk and with consistent quality.
The figures NEET uses come from the time the syllabus was framed: about 30 recombinant therapeutics had been approved for human use worldwide, and 12 of them were being marketed in India. (Today there are hundreds — insulin, growth hormone, blood-clotting factors, interferons, erythropoietin, monoclonal antibodies — but in an exam the answer is 30 and 12.)
- Mature insulin is made of two short polypeptide chains: chain A (21 amino acids) and chain B (30 amino acids), held together by disulphide bridges (two between the chains and one within chain A).
- In mammals, including humans, insulin is synthesised as a prohormone — proinsulin, a single chain with an extra stretch called the C peptide joining the end of chain B to the start of chain A. (Like a pro-enzyme, a prohormone has to be processed before it becomes fully mature and functional.)
- The C peptide is not present in mature insulin: it is removed during maturation, inside the secretory vesicles of the β-cells of the islets of Langerhans.
- For decades the insulin used to treat diabetes was extracted from the pancreas of slaughtered cattle and pigs. Animal insulin differs slightly from human insulin, and some patients developed allergy or other reactions to the foreign protein.
The main challenge was getting insulin assembled into its mature form. In 1983 the American company Eli Lilly solved it like this:
- Two DNA sequences were prepared, one corresponding to chain A and one to chain B of human insulin.
- They were introduced into plasmids of E. coli (separately), and the bacteria produced the two insulin chains.
- Chains A and B were produced separately, extracted, and combined by creating disulphide bonds to form human insulin.
The product is called Humulin. It is the human hormone itself, so it avoids the allergic reactions caused by animal insulin, and its supply no longer depends on slaughterhouses.
In the lab below, choose E. coli, 1983 and step to the point where the bacteria have finished making protein. How many disulphide bridges does the protein in each culture have at that stage?
Insulin shows how to make a drug; the same logic makes a vaccine. A vaccine has to show the immune system the antigen of a pathogen (Section 8.1) — and an antigen is usually a protein, coded by a gene.
Recombinant DNA technology allows the antigenic polypeptides of a pathogen to be produced in bacteria or yeast. A vaccine made of such a protein is a recombinant (subunit) vaccine: it contains one antigen, not the whole pathogen, so it cannot cause the disease, and it can be made on a large scale, safely and cheaply.
- Hepatitis B vaccine — the gene for the surface antigen of the hepatitis B virus (HBsAg) is put into yeast (Saccharomyces cerevisiae). The yeast is grown in bioreactors, the antigen is extracted and purified (downstream processing) and formulated as the vaccine. It was the first recombinant vaccine for human use and is given to newborns in India's immunisation programme.
- DNA vaccines — instead of the antigen protein, the gene for it (carried in a plasmid) is injected; the person's own cells make the antigen and the immune system responds to it.
Production steps follow Key fact 9.5 of Section 9.1: isolate the antigen gene → ligate it into a vector → transform the host (yeast) → culture in a bioreactor → extract and purify the antigen → formulate, test for quality and safety.
In the 1983 method of making human insulin, what was introduced into E. coli?
Biotechnology in Medicine II — Gene Therapy, Stem Cells and Molecular Diagnosis
Insulin injections replace a missing product every day for life. Gene therapy asks a bolder question: could we replace the faulty gene instead? And molecular diagnosis asks: could we see a disease in its genes and proteins before it shows any symptom?
Gene therapy is a collection of methods that allows the correction of a gene defect diagnosed in a child or an embryo. Genes are inserted into a person's cells and tissues to treat a disease: a normal gene is delivered into the individual or embryo to take over the function of, and compensate for, the non-functional gene.
If only body (somatic) cells such as blood cells are corrected, the change helps the patient but is not inherited. If the gene could be introduced into cells at an early embryonic stage, the correction would be permanent.
- Given in 1990 to a four-year-old girl with adenosine deaminase (ADA) deficiency.
- ADA is an enzyme crucial for the immune system to function. The disorder is caused by the deletion of the gene for ADA.
- Earlier treatments: in some children, bone marrow transplantation; in others, enzyme replacement therapy (functional ADA given by injection). Neither is completely curative.
- Gene therapy: lymphocytes from the patient's blood are grown in a culture outside the body; a functional ADA cDNA is introduced into them using a retroviral vector; the cells are then returned to the patient.
- Lymphocytes are not immortal, so the patient needs periodic infusions of genetically engineered lymphocytes. If the ADA gene isolated from marrow cells were introduced into cells at early embryonic stages, it could be a permanent cure.
The ADA case points to the cells that make a cure permanent: cells that keep dividing for life and give rise to other cells. These are stem cells, and growing and using them is one of the fastest-growing parts of medicine.
A stem cell is an undifferentiated cell that can (i) renew itself — divide to make more stem cells — and (ii) differentiate into specialised cells. Stem cells are classified by how many kinds of cell they can form (their potency):
| Potency | Can form | Example |
|---|---|---|
| Totipotent | every cell of the body and the extra-embryonic tissues (placenta) | the zygote and the cells of its first few divisions |
| Pluripotent | all cell types of the body, but not a whole organism | embryonic stem cells from the inner cell mass of the blastocyst |
| Multipotent | several related cell types | adult stem cells, e.g. haematopoietic stem cells of the bone marrow (all blood cells); stem cells of umbilical cord blood |
| Unipotent | one cell type | muscle satellite cells (muscle fibres) |
Stem cell technology is the isolation, culture and use of stem cells to repair or replace damaged cells and tissues (regenerative medicine). Established uses: bone marrow (haematopoietic stem cell) transplantation for leukaemia, thalassaemia and immune deficiencies such as ADA deficiency; umbilical cord blood banking; growing skin for burn patients and corneal stem cells to restore sight. Under research: repairing heart muscle, nerve cells and pancreatic β-cells. A newer source is induced pluripotent stem (iPS) cells — adult cells reprogrammed, by adding a few genes, to behave like embryonic stem cells. Using embryonic stem cells raises an ethical issue, because an early embryo is destroyed to obtain them.
Medicine depends on finding a disease early. Conventional methods — analysis of serum and urine — can detect an infection only once the pathogen has multiplied enough, often after symptoms appear. Recombinant DNA technology, PCR and ELISA can detect it far earlier.
- PCR amplifies the nucleic acid of a pathogen, so a very low concentration of a bacterium or virus can be detected — at a time when the symptoms of the disease are not yet visible. It is routinely used to detect HIV in suspected AIDS patients, to detect mutations in genes in suspected cancer patients, and to identify many other genetic disorders.
- Probe and autoradiography. A single-stranded DNA or RNA tagged with a radioactive molecule (a probe) is allowed to hybridise to its complementary DNA in a clone of cells, followed by detection using autoradiography. The clone having a mutated gene will not appear on the photographic film, because the probe is not complementary to the mutated gene.
- ELISA (enzyme-linked immunosorbent assay) is based on the principle of antigen–antibody interaction. Infection by a pathogen can be detected by the presence of its antigens (proteins, glycoproteins, etc.) or by detecting the antibodies synthesised against the pathogen.
| Method | Detects | Principle | Typical use |
|---|---|---|---|
| Serum / urine analysis | products of an established infection | conventional biochemistry, microscopy | after symptoms appear |
| PCR | pathogen's DNA or RNA; mutated genes | amplification of a target nucleic acid ($2^{n}$ copies) | HIV, cancer mutations, genetic disorders — very early |
| Probe + autoradiography | presence or absence of a particular sequence | hybridisation of a labelled complementary strand | picking out a clone with a mutated gene |
| ELISA | pathogen's antigens, or antibodies against it | antigen–antibody binding, revealed by an enzyme's coloured product | HIV screening, many infections |
In the first clinical gene therapy (1990), how was the functional ADA gene delivered?
Biotechnology in Agriculture — GM Crops, Bt Toxin and RNA Interference
There are three options for increasing food production: agro-chemical-based agriculture, organic agriculture and genetically engineered crop-based agriculture. The Green Revolution succeeded in tripling the food supply, but it was still not enough for a growing population. Its higher yields came partly from improved crop varieties, but mainly from better management and the use of agrochemicals — fertilisers and pesticides — which are often too expensive for farmers in the developing world, and which harm the environment. Further increases in yield from the existing varieties are not possible by conventional breeding. Genetically modified crops offer a way to grow more while using fewer chemicals.
Plants, bacteria, fungi and animals whose genes have been altered by manipulation are called genetically modified organisms (GMOs). An organism that carries and expresses a gene from another species is transgenic; the gene is a transgene. Plant genes are usually changed with the Ti-plasmid vector of Agrobacterium tumefaciens or by biolistics (Section 9.1).
- made crops more tolerant to abiotic stresses — cold, drought, salt, heat;
- reduced reliance on chemical pesticides (pest-resistant crops);
- helped to reduce post-harvest losses (e.g. tomatoes whose ripening is delayed, so they stay firm longer);
- increased the efficiency of mineral usage by plants — this prevents early exhaustion of the fertility of the soil;
- enhanced the nutritional value of food — e.g. Golden rice, a vitamin A-enriched rice (its grains make β-carotene, the precursor of vitamin A, which gives them their golden colour).
GM has also been used to create tailor-made plants that supply alternative resources to industries — starches, fuels and pharmaceuticals.
The best-known application is pest resistance. A pest-resistant crop makes its own protection, so the farmer sprays less insecticide. NEET concentrates on two ways of achieving it: a bacterial toxin gene (Bt crops) and RNA interference.
Bt toxin is produced by the soil bacterium Bacillus thuringiensis ("Bt" for short). Some strains of B. thuringiensis produce proteins that kill certain insects — lepidopterans (tobacco budworm, armyworm), coleopterans (beetles) and dipterans (flies, mosquitoes). During a particular phase of its growth the bacterium forms protein crystals that contain the toxic insecticidal protein.
The toxin is coded by a gene named cry; there are many of them, and most Bt toxins are specific to a group of insects, so the gene chosen depends on the crop and the targeted pest:
| Gene | Protein | Controls |
|---|---|---|
| cryIAc and cryIIAb | CryIAc, CryIIAb | cotton bollworms |
| cryIAb | CryIAb | corn borer |
The Bt toxin gene has been cloned from the bacterium and expressed in plants, giving them resistance to insects without the need for insecticides — in effect the plant makes a bio-pesticide. Examples: Bt cotton, Bt corn, rice, tomato, potato and soybean. (Gene names are written in lower-case italics, cry; the proteins they code for start with a capital, Cry. In Indian texts the numbers are often printed as Roman numerals, cryIAc; in research papers as cry1Ac.) Bt cotton was approved for cultivation in India in 2002 and now covers most of the country's cotton area.
- In the bacterium (and in the Bt plant) the toxin exists as an inactive protoxin, so it does not harm the cell that makes it.
- When an insect eats it, the inactive toxin is converted into its active form by the alkaline pH of the insect's gut, which solubilises the crystals.
- The activated toxin binds to the surface of the midgut epithelial cells and creates pores, which cause cell swelling and lysis and eventually the death of the insect.
Mammals, including humans, are not affected: their stomach is acidic rather than alkaline, the protein is digested like any other, and their gut cells lack the specific receptors to which the activated toxin binds.
Not every pest is an insect. The nematode Meloidogyne incognita infects the roots of tobacco plants and causes a great reduction in yield. It was defeated by switching off one of its own genes — from inside the plant.
RNA interference (RNAi) takes place in all eukaryotic organisms as a method of cellular defence. It involves the silencing of a specific mRNA by a complementary double-stranded RNA (dsRNA) molecule that binds to the mRNA and prevents its translation. The source of the complementary RNA in nature can be an infection by viruses having RNA genomes, or mobile genetic elements (transposons) that replicate via an RNA intermediate.
- Using Agrobacterium vectors, nematode-specific genes were introduced into the host plant (tobacco).
- The introduced DNA was arranged so that it produced both sense and anti-sense RNA in the host cells.
- These two RNAs, being complementary to each other, formed a double-stranded RNA (dsRNA) that initiated RNAi.
- The dsRNA silenced the specific mRNA of the nematode when the nematode fed on the plant: the protein it codes for could not be made.
- The parasite could not survive in a transgenic host expressing the specific interfering RNA — the plant was protected.
In the tracer below, choose RNAi in tobacco and the transgene that makes sense RNA only. Run it to the last stage. What happens to the nematode?
Why does Bt toxin become active in a bollworm's gut?
Transgenic Animals, Biosafety, Patents and Biopiracy
The same micro-injection and viral vectors that deliver genes into animal cells (Section 9.1) can change a whole animal, if the gene is put into a fertilised egg or an early embryo. Every cell of the resulting animal then carries the new gene, and so do its offspring.
Animals whose DNA has been manipulated to possess and express an extra (foreign) gene are called transgenic animals. Transgenic rats, rabbits, pigs, sheep, cows and fish have been produced, but over 95 % of all existing transgenic animals are mice.
- Normal physiology and development — to study how genes are regulated and how they affect the normal functions of the body and its development, e.g. the study of complex factors involved in growth such as insulin-like growth factor. A gene that alters the formation of such a factor is introduced and the effects are watched.
- Study of disease — many transgenic animals are designed to understand how genes contribute to the development of disease; they serve as models for human diseases, so new treatments can be investigated. Models exist for cancer, cystic fibrosis, rheumatoid arthritis and Alzheimer's disease.
- Biological products — medicines needed to treat some human diseases can be made in animals carrying the gene for the product: e.g. human protein α-1-antitrypsin, used to treat emphysema; similar attempts for treating phenylketonuria (PKU) and cystic fibrosis. In 1997 the first transgenic cow, Rosie, produced human protein-enriched milk (2.4 grams per litre). The milk contained the human alpha-lactalbumin and was nutritionally a more balanced product for human babies than natural cow milk.
- Vaccine safety testing — transgenic mice are being developed for use in testing the safety of vaccines before they are used on humans; they are used to test the safety of the polio vaccine. If successful and reliable, they could replace the use of monkeys.
- Chemical safety testing (toxicity testing) — the procedure is the same as for testing the toxicity of drugs. Transgenic animals carry genes that make them more sensitive to toxic substances than non-transgenic animals; they are exposed to the substances and the effects studied, so results are obtained in less time.
Changing the genes of organisms and releasing them into fields, foods and medicines raises questions that science alone cannot settle: who checks that a GM organism is safe, and who owns a gene, a variety or the knowledge of a traditional medicine?
The manipulation of living organisms by the human race cannot go on any further without regulation. Introducing a GM organism may have unpredictable results when it enters an ecosystem — for example, the transgene may spread to wild relatives, non-target organisms may be harmed, pests may evolve resistance, or a new protein in food may cause allergy. Biosafety is the set of rules and tests that keep such risks low.
The Indian Government has set up organisations such as the GEAC (Genetic Engineering Approval Committee, renamed the Genetic Engineering Appraisal Committee in 2010), which makes decisions regarding the validity of GM research and the safety of introducing GM organisms for public services. A GM crop such as Bt cotton can be grown commercially in India only after GEAC approval.
A patent is a right granted by a government to an inventor that stops others from commercially using the invention. When patents are granted for biological entities and for products derived from them, they are called biopatents. Companies have applied for patents on products and technologies that make use of genetic materials, plants and other biological resources that have long been identified, developed and used by farmers and indigenous people of a country.
- India has an estimated 2 lakh varieties of rice, and 27 documented varieties of Basmati are grown in India alone; Basmati is distinct for its unique aroma and flavour. In 1997 an American company got patent rights on Basmati rice through the US Patent and Trademark Office. This allowed it to sell a "new" variety of Basmati in the US and abroad — a variety actually derived from Indian farmers' varieties, crossed with semi-dwarf varieties and claimed as an invention.
- Other people have tried to patent uses, products and processes based on Indian traditional herbal medicines, e.g. turmeric and neem.
Biopiracy is the term used to refer to the use of bio-resources by multinational companies and other organisations without proper authorisation from the countries and people concerned, without compensatory payment. Industrialised nations are rich financially but poor in biodiversity and traditional knowledge; the developing and under-developed world is rich in both. There is growing realisation of this injustice: some nations are developing laws to prevent unauthorised exploitation of their bio-resources and traditional knowledge. The Indian Parliament has cleared the second amendment of the Indian Patents Bill, which takes such issues into consideration, including patent terms, emergency provisions and research and development initiative; and India's Biological Diversity Act (2002) requires approval and benefit-sharing before its bio-resources are used commercially.
Which statement about the transgenic cow Rosie is correct?
1. Insulin numbers. Chain A 21, chain B 30 amino acids; joined by disulphide bridges. The C peptide is in proinsulin, not in mature insulin. Eli Lilly, 1983: two DNA sequences (A and B) in plasmids of E. coli; chains made separately and then joined.
2. Recombinant therapeutics: about 30 approved worldwide, 12 marketed in India. Hepatitis B vaccine: antigen made in yeast.
3. ADA deficiency. 1990, a four-year-old girl; cause: deletion of the ADA gene; cells treated: lymphocytes; vector: retrovirus; what goes in: functional ADA cDNA. Bone-marrow transplant and enzyme replacement are not completely curative; lymphocytes are not immortal → periodic infusions.
4. Diagnosis. PCR — nucleic acid, very low concentration, before symptoms (HIV, cancer mutations). ELISA — antigen–antibody interaction (antigens or antibodies). In probe hybridisation the mutated clone does not appear on the film.
5. Bt toxin. From Bacillus thuringiensis; inactive protoxin crystals; activated by the alkaline (not acidic) gut pH; binds midgut epithelial cells, makes pores → swelling, lysis. Kills lepidopterans, coleopterans and dipterans.
6. The cry genes. cryIAc and cryIIAb → cotton bollworms; cryIAb → corn borer. Gene in italics and lower case (cry), protein capitalised (Cry).
7. RNAi. Pest: Meloidogyne incognita, a nematode of tobacco roots; vector: Agrobacterium; the transgene makes sense and anti-sense RNA → dsRNA → silences the nematode's mRNA (not the plant's). Natural sources of dsRNA: RNA viruses, transposons with an RNA intermediate.
8. GM crops. Golden rice — vitamin A (β-carotene), not iron. Five benefits: abiotic-stress tolerance, less pesticide, fewer post-harvest losses, better mineral use, nutrition.
9. Transgenic animals. Over 95 % are mice. Rosie, 1997, alpha-lactalbumin, 2.4 g/L. α-1-antitrypsin → emphysema. Transgenic mice test polio vaccine safety.
10. Ethics. GEAC — validity of GM research and safety of release. Basmati patent 1997, American company, US Patent and Trademark Office; 27 documented Basmati varieties in India. Biopiracy = use of bio-resources without authorisation and without compensatory payment.
Not in the NMC NEET (UG) syllabus; optional background for the curious.
Insulin after 1983. Making two chains and joining them correctly was inefficient. From the late 1980s manufacturers switched to making a single-chain proinsulin (or a shortened precursor) in E. coli or yeast, folding it so the three disulphide bridges form in the right places, and then cutting out the C peptide with enzymes in a tank — copying in a bioreactor what the β-cell does naturally. Modern "insulin analogues" change one or two amino acids so the hormone acts faster or lasts longer.
mRNA vaccines. The COVID-19 vaccines of 2020–21 went one step beyond DNA vaccines: they inject the mRNA for a viral surface protein, wrapped in tiny fat droplets. The person's ribosomes translate it, and the mRNA is soon broken down.
Gene editing. CRISPR–Cas9, a bacterial defence system turned into a tool, cuts DNA at a site chosen by a short guide RNA, so a faulty gene can be repaired in place instead of a normal copy being added. In 2023 the first CRISPR-based treatment, for sickle-cell disease and β-thalassaemia, was approved: the patient's own blood stem cells are edited outside the body and returned — gene therapy and stem cell technology together.
Exercises
- 1 What are recombinant therapeutics? Why are they preferred to similar products isolated from non-human sources? Give the numbers of approved recombinant therapeutics worldwide and in India that NEET uses.
- 2 Name the two chains of mature insulin, give the number of amino acids in each, and name the bonds that hold them together.
- 3 What is the C peptide? In which form of insulin is it present, and when is it removed?
- 4 Describe how human insulin was first produced by recombinant DNA technology: the year, the company, the host, the vector and the way the final hormone was assembled.
- 5 Why did insulin from cattle and pigs not suit every diabetic patient?
- 6 A molecule of human proinsulin contains 86 amino acids. How many amino acids are removed when it matures into insulin?
- 7 For the hepatitis B vaccine, name the antigen, the host organism that makes it, and explain why the vaccine cannot cause hepatitis B.
- 8 How many of these are made by recombinant DNA technology: human insulin from E. coli; hepatitis B vaccine from yeast; penicillin from Penicillium; insulin extracted from pig pancreas; human growth hormone made in bacteria?
- 1 Define gene therapy. Why would correcting a gene in an early embryo give a permanent cure while correcting blood cells does not?
- 2 What is adenosine deaminase, what causes its deficiency, and when and on whom was the first clinical gene therapy performed?
- 3 Name two treatments for ADA deficiency that were used before gene therapy. Why is neither completely curative?
- 4 Describe, step by step, the gene therapy given for ADA deficiency. Why must it be repeated?
- 5 Define a stem cell. Arrange totipotent, multipotent and pluripotent cells in decreasing order of potency, giving one example of each.
- 6 What ethical objection is raised against embryonic stem cells? How do induced pluripotent stem cells avoid it?
- 7 Why can PCR detect an infection before any symptom appears? Give three uses of PCR in diagnosis.
- 8 State the principle of ELISA. Name the two kinds of molecule it can detect to show an infection.
- 9 200 bacterial clones of a human gene are screened with a radioactive probe complementary to the normal gene. After autoradiography, 197 spots appear on the film. How many clones carry the mutated gene?
- 1 Name the three options for increasing food production. Why is the Green Revolution approach not enough on its own?
- 2 List five ways in which genetic modification has made crop plants more useful.
- 3 What is Golden rice, and which deficiency is it meant to fight?
- 4 Name the source of Bt toxin and the three groups of insects killed by different Bt toxins, with one example of each.
- 5 Explain why Bt toxin does not kill the bacterium that makes it, and describe the steps by which it kills an insect larva.
- 6 Match: (a) cryIAc (b) cryIAb (c) cryIIAb — with (i) corn borer (ii) cotton bollworm. One item of List-II may be used twice.
- 7 What is RNA interference? Name two natural sources of the complementary RNA.
- 8 Describe how nematode-resistant tobacco plants were produced. Name the nematode.
- 9 Applied (illustrative numbers). A farmer used to spray insecticide 8 times a season on 4 hectares of cotton, at $\text{₹}\,1500$ per hectare per spray. After switching to Bt cotton he needs only 2 sprays (against sucking pests that Bt toxin does not kill). How much does he save on spraying per season?
- 1 Define a transgenic animal. Which animal makes up over 95 % of existing transgenic animals, and why do you think it is so popular?
- 2 List the five reasons for producing transgenic animals, with one example for each.
- 3 Give the year, the human protein and the protein's concentration in the milk of Rosie. Why was the milk useful?
- 4 Which human disease is treated with α-1-antitrypsin made in transgenic animals?
- 5 Why could transgenic mice replace monkeys in testing the safety of the polio vaccine?
- 6 What is the GEAC? State its two functions.
- 7 Define biopiracy, and explain the Basmati case. Name two other Indian bio-resources that have been the subject of patent attempts.
- 8 Applied (illustrative numbers). A transgenic goat gives 3 litres of milk a day containing 5 g of a human therapeutic protein per litre. Purification recovers 80 % of it. One patient needs 12 g of the protein per week. How many patients can one goat supply?
E1. NEET · MCQ Statement I: In the first clinical gene therapy, a functional ADA cDNA was introduced into lymphocytes taken from the patient, using a retroviral vector. Statement II: Because lymphocytes are immortal, a single infusion of the engineered lymphocytes gave the patient a permanent cure. Choose the correct option. (A) Both statements I and II are correct (B) Both statements I and II are incorrect (C) Statement I is correct but statement II is incorrect (D) Statement I is incorrect but statement II is correct
E2. NEET · MCQ Assertion (A): The Bt toxin protein does not kill the bacterium Bacillus thuringiensis that produces it. Reason (R): In the bacterium, the toxin is present as an inactive protoxin, which becomes active only in the alkaline gut of an insect. (A) Both A and R are true and R is the correct explanation of A (B) Both A and R are true but R is not the correct explanation of A (C) A is true but R is false (D) A is false but R is true
E3. NEET · MCQ Match List-I with List-II. List-I: (a) cryIAb (b) cryIAc (c) human alpha-lactalbumin (d) α-1-antitrypsin. List-II: (i) treatment of emphysema (ii) corn borer (iii) cotton bollworm (iv) milk of the transgenic cow Rosie. (A) a-iii, b-ii, c-iv, d-i (B) a-ii, b-iii, c-i, d-iv (C) a-iv, b-iii, c-ii, d-i (D) a-ii, b-iii, c-iv, d-i
E4. NEET · MCQ How many of the following statements are correct? (i) Golden rice is a vitamin A-enriched rice. (ii) Over 95 % of all existing transgenic animals are mice. (iii) ELISA is based on the principle of antigen–antibody interaction. (iv) The 1997 patent on Basmati rice was granted by the Indian Patent Office. (v) In RNA interference, a complementary double-stranded RNA silences a specific mRNA. (vi) Bt toxin is activated by the acidic pH of the insect's gut. (A) three (B) four (C) five (D) two
E5. NEET · MCQ The diagram shows a molecule made in the β-cells of the pancreas, with four parts labelled P, Q, R and S. Which labelled part is absent from mature insulin, and how many amino acids does chain P contain?(A) Q; P contains 21 amino acids (B) Q; P contains 30 amino acids (C) R; P contains 21 amino acids (D) S; P contains 30 amino acids
E6. NEET · MCQ Arrange the steps of gene therapy for ADA deficiency in the correct order: (i) lymphocytes are grown in a culture outside the body (ii) blood is taken from the patient (iii) a functional ADA cDNA is introduced into the lymphocytes with a retroviral vector (iv) the engineered lymphocytes are infused into the patient. (A) i, ii, iii, iv (B) ii, iii, i, iv (C) iii, ii, i, iv (D) ii, i, iii, iv
Research question. ELISA and PCR can both diagnose an infection such as HIV. Which one detects an infection sooner, and when a screening test comes back positive, how likely is it that the person is really infected?
Why it matters. Blood banks in Mumbai, Nairobi and Bogotá screen millions of donations a year; clinics must decide whom to treat. An antibody ELISA is cheap and fast but cannot see an infection until the body has made antibodies — the window period. PCR sees the virus's own nucleic acid much earlier but costs more and needs a laboratory. And because infection is rare among donors, even a very accurate test produces many false alarms — which is why a positive screen is always confirmed by a second test.
What to do.
- (Illustrative numbers.) After an infection, the virus first appears in the blood on day 3 at 1 copy per mL, and its level doubles every day. A PCR test detects it once it reaches 50 copies per mL. An antibody ELISA becomes positive on day 25. On which day does PCR first detect the infection, and how many days shorter is its window period?
- An ELISA kit is tried on 1000 people known to be infected and 1000 known to be uninfected. It is positive for 995 of the infected and negative for 990 of the uninfected. Calculate its sensitivity (the percentage of infected people it detects) and its specificity (the percentage of uninfected people it correctly calls negative).
- The kit is used to screen 100 000 blood donors, of whom 0.5 % are infected. How many true positives and how many false positives do you expect? What percentage of the positive results are true (the positive predictive value)?
- Explain, from your answers, why a positive screening ELISA is followed by a confirmatory test, and why blood banks in some countries add a nucleic-acid (PCR-type) test.
Tools: a calculator or a spreadsheet; the PCR cycle counter of Section 9.1 for the idea of amplification.
Hand in: a timeline marking the two detection days, your sensitivity, specificity and predictive-value calculations in a table, and a paragraph comparing ELISA and PCR (what each detects, speed, cost, when each is the better choice).
Going further. Find out what a "fourth-generation" HIV test detects (both an antigen and antibodies) and how much it shortens the window period compared with an antibody-only test.
🧪 Self-check quiz
Q1. Transgenic tobacco plants were protected by RNA interference against
Q2. The GEAC set up by the Government of India
Q3. A very low concentration of a virus in a patient, before any symptom appears, is best detected by
Q4. Golden rice is a genetically modified rice enriched in
Q5. The first clinical gene therapy, in 1990, was given to treat